Načítá se...
Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
BACKGROUND: Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and safety o...
Uloženo v:
| Vydáno v: | J Ovarian Res |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7079537/ https://ncbi.nlm.nih.gov/pubmed/32183851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-020-00629-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|